retatrutide tingling sensation Retatrutide: The New Triple-Agonist Weight Loss Treatment π§ β¨ Letβs talk about dysesthesia
Description
Have a pharma update request
The optimal dosing, duration of treatment, patient selection criteria, and long-term efficacy and safety for this potential indication are unknown
10.7554/eLife.54083 [DOI] [PMC free article] [PubMed] [Google Scholar] Sdzikowska A., Szablewski L
Lancet 1964;2:9957
Interestingly, the STEP-8 study 22 revealed a higher incidence of psychiatric events with liraglutide 3 mg (15.0%) compared to semaglutide 2.4 mg (5.6%) and placebo (10.6%)
